AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since HumiraThe Motley Fool • 08/20/19
AbbVie's FDA Approval For RINVOQ Sets Up First Phase Of Deployment Plan To Counter Humira IssueSeeking Alpha • 08/18/19
How AbbVie Plans To Take On Pfizer, Lilly — And Kick Its Humira HabitInvestors Business Daily • 08/16/19
These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024The Motley Fool • 08/04/19
Abbvie Inc (ABBV) EVP, Chief Strategy Officer Henry O Gosebruch Bought $2 million of SharesGuruFocus • 07/31/19
AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 07/26/19